Qiagen has filed a patent for compositions and methods to detect, diagnose, and characterize immune responses to SARS-CoV-2 in COVID-19 patients. The patent involves using synthetic peptides from SARS-CoV-2 Spike proteins to detect antigen-specific T-cell responses. GlobalData’s report on Qiagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Qiagen, Nucleoside chemical synthesis was a key innovation area identified from patents. Qiagen's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Composition for covid-19 diagnosis and t-cell immune response detection
A patent application (Publication Number: US20240027450A1) discloses a composition designed for diagnosing or predicting the course of Covid-19, as well as detecting a specific immune response to SARS-CoV-2. The composition includes isolated oligopeptides containing T-cell epitopes from the SARS-CoV-2 Spike protein S1 or S2 region, with specific amino acid sequences outlined in the patent claims. These oligopeptides aim to trigger a T-cell immune response, aiding in the identification of antigen-specific cell-mediated immune activity in response to the virus.
Furthermore, the patent application describes a method for detecting SARS-CoV-2 spike protein antigen-specific cell-mediated immune response in a biological sample. By incubating the sample with specific peptide compositions containing oligopeptides with defined amino acid sequences, the method aims to stimulate a T-cell immune response indicator, such as interferon-gamma, indicative of the presence of SARS-CoV-2 spike protein-specific immune activity. The method also allows for variations in the peptide compositions and biological sample types, offering a versatile approach to identifying immune responses to the virus in individuals, including those who have received a SARS-CoV-2 vaccine.
To know more about GlobalData’s detailed insights on Qiagen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
